JAK inhibitor, a new player for treatment-refractory microscopic colitis.
(2023) Intestinal Research — Vol. 21, n° 3, p. 411-412 (2023)
Files
DruezAIntestRes2023.pdf
Open Access - Adobe PDF
- 100.37 KB
Details
- Authors
- Abstract
- (en) Microscopic colitis (MC), including collagenous colitis (CC) and lymphocytic colitis (LC), has emerged as a common cause of chronic diarrhea with an annual overall incidence of 4.14 per 100,000 person-years (CC) and 4.85 per 100,000 person-years (LC), respectively. While most patients experience an indolent disease course with occasional relapses, it undeniably affects their quality of life. No curative therapy exists, but most patients respond well to budesonide, which represents the treatment of choice with up to 90% achieving clinical remission after induction therapy. However, in a European multicenter prospective registry, 49% of 381 patients had persistent activity or frequently relapsing (≥ 2/year) disease when budesonide was stopped. [...]
- Affiliations
Citations
Druez, A., Travis, S., & Rahier, J.-F. (2023). JAK inhibitor, a new player for treatment-refractory microscopic colitis. Intestinal Research, 21(3), 411-412. https://doi.org/10.5217/ir.2023.00030 (Original work published 2023)